Purchase this article with an account.
Johannes Gonnermann, Necip Torun, Matthias Klamann, Anna-Karina Maier, Peter Rieck, Eckart Bertelmann; Posterior iris-claw aphakic intraocular lens implantation in children. Invest. Ophthalmol. Vis. Sci. 2013;54(15):1845.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the indications, visual outcomes, and complication rate after posterior implantation of an iris-claw aphakic intraocular lens (IOL) in children.
Eyes without adequate capsule support had posterior chamber iris-claw aphakic IOL implantation (Verisyse/Artisan) between 2007 and 2012.
This non-comparative retrospective cohort study comprised 7 eyes (4 children). The mean follow-up was 31 months (range 10 to 64 months). In all eyes, the mean postoperative best spectacle-corrected visual acuity (0.13 ± 0.17 logMAR) was statistically significantly better at the last follow-up than 1 day preoperatively (0.60 ± 0.39 logMAR) (P < .05). The mean endothelial cell loss decreased from 3013 ± 155 cells/mm2 preoperatively to 2831 ± 236 cells/mm2 at last follow-up, representing a mean endothelial cell loss of 6.4%. No secondary glaucoma or pupillary block occurred after surgery in any eye.
The posterior implantation technique of Verisyse/Artisan aphakic iris-claw IOL provided good visual outcomes with a favorable complication rate and can be used as a reasonable alternative for a wide range of indications in pediatric eyes without adequate capsule support.
This PDF is available to Subscribers Only